13 results
·
29ms
·
Sources: EU EUDAMED, US FDA
Filters
Regulation: Us FDA
×
CARESCAPE R860
FDA 510(k)
FDA Class 2
·Anesthesiology
NA
FDA UDI
Smith & Nephew, Inc.·00885554010824·5.5 MM BLUNT OBTURATOR FOR 5.5 MM
...
DG Gel 8 A/B/D
FDA UDI
DIAGNOSTIC GRIFOLS SA·08437014205930·The DG Gel 8 A/B/D card is for the determinatio...
DG Gel 8 A/B/D
FDA UDI
DIAGNOSTIC GRIFOLS SA·08437014205039·The DG Gel 8 A/B/D card is for the determinatio...
PROTECTOR, INJECTOR, CONNECTOR
FDA 510(k)
FDA Class 2
·General Hospital
DILON 6800 ACELLA (ACELLA)
FDA 510(k)
FDA Class 1
·Radiology
PULSE GEN MODEL 101
FDA Adverse Event
Malfunction
·CYBERONICS, INC.·Product code LYJ·August 8, 2011
LIFEVEST WCD 4000 SYSTEM
FDA Adverse Event
Malfunction
·ZOLL MANUFACTURING CORPORATION·Product code MVK·August 8, 2014
ALTRUA
FDA Adverse Event
Injury
·GUIDANT CRM CLONMEL IRELAND·Product code NVZ·July 8, 2013
ACUSON S Family Ultrasound Systems at software versions VC25D, VC30A and VC30B; (S2000, S3000 and S1000 systems) Siemens Medical Solutions USA, Inc. Ultrasound imaging systems.
FDA Enforcement
Class II
·Terminated·Siemens Medical Solutions USA, Inc.·July 9, 2014
ACUSON S 1000, ACUSON S 2000, or ACUSON S 3000 ultrasound systems with software version C3, C3, C3, or C1. Model numbers: 10041461, 10440017 S 2000 system 10441730 S 3000 system 10441701 S 1000 system Radiology: The ultrasound imaging systems are intended for the following applications: Fetal, Abdominal, Intraoperative, Pediatric, Small Parts, Transcranial, OB/GYN, Cardiac, Pelvic, Neonatal/Adult Cephalic, Vascular, Musculoskeletal, Superficial Musculoskeletal, and Peripheral Vascular applications.
FDA Enforcement
Class II
·Terminated·Siemens Medical Solutions USA, Inc.·August 5, 2015
Model Number L211 PROPONENT DR SL MRI Pacemaker
FDA Enforcement
Class I
·Ongoing·Boston Scientific Corporation·October 22, 2025
PROPONENT DR Pacemaker, SL (Model Number L201), (VDD) SL (Model Number L209), SL MRI (Model Number L211), EL (Model Number L221), and EL MRI (Model Number L231).
FDA Enforcement
Class I
·Ongoing·Boston Scientific Corporation·January 22, 2025